

## Quick reference guide

# Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

### Guidance

- 1 Naftidrofuryl oxalate is recommended as an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. Treatment with naftidrofuryl oxalate should be started with the least costly licensed preparation.
- 2 Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the treatment of intermittent claudication in people with peripheral arterial disease.
- 3 People currently receiving cilostazol, pentoxifylline and inositol nicotinate should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

### Implementation tools

NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website ([www.nice.org.uk/guidance/TA223](http://www.nice.org.uk/guidance/TA223)).

- Costing template and report to estimate the national and local savings and costs associated with implementation.
- Audit support for monitoring local practice.

### Further information

#### Ordering information

You can download the following documents from [www.nice.org.uk/guidance/TA223](http://www.nice.org.uk/guidance/TA223)

- A quick reference guide (this document) – the recommendations.
- ‘Understanding NICE guidance’ – a summary for patients and carers.
- The NICE guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email [publications@nice.org.uk](mailto:publications@nice.org.uk) and quote:

- N2555 (quick reference guide)
- N2556 (‘Understanding NICE guidance’).

### NICE technology appraisal guidance 223

The guidance was developed using the NICE multiple technology appraisal process. NICE technology appraisal guidance is about the use of new and existing medicines and treatments in the NHS in England and Wales.

## Related NICE guidance

For information about NICE guidance that has been issued or is in development, see [www.nice.org.uk](http://www.nice.org.uk)

### Published

- Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of NICE technology appraisal guidance 90). NICE technology appraisal guidance 210 (2010). Available from [www.nice.org.uk/guidance/TA210](http://www.nice.org.uk/guidance/TA210)

### Under development

- Lower limb peripheral arterial disease. NICE clinical guideline. Publication expected October 2012.

## Updating the appraisal

This technology appraisal will be considered for review in May 2014. Information about the progress of a review will be available at [www.nice.org.uk/guidance/TA223](http://www.nice.org.uk/guidance/TA223)

This guidance represents the view of NICE, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

© National Institute for Health and Clinical Excellence, 2011. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.